Amryt Pharma: EIB Funds Secure Phase III For Rare Skin Disease Candidate And Cholesterol Drug License

Not many 18-month old rare and orphan disease-focused biotech companies have an approved product in their portfolio. Even fewer have persuaded the European Investment Bank to make a direct investment into their business. Amryt Pharma can claim both.

Amryt Pharma PLC was formed in 2015 through two acquisitions, one of German firm Birken – which brought in its lead product Episalvan (AP101), and the other Som Pharmaceuticals of Switzerland – which has a next generation therapy for acromegaly and Cushing's disease in preclinical development.

Amryt made its presence known by arriving onto the London Stock Exchange's AIM market earlier this year through a reverse...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip